How the product works:
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It enhances glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and reduces appetite, leading to effective blood glucose control and sustained weight loss.
Who it is recommended for:
Clinical studies and evidence:
Tirzepatide has been evaluated in the global SURPASS clinical trial program. Studies demonstrated significant reductions in HbA1c levels, substantial weight loss, and improved metabolic outcomes compared to standard GLP-1 receptor agonists, confirming its efficacy and safety.
Indicated for the treatment of type 2 diabetes mellitus to improve glycemic control. The medication lowers fasting and postprandial glucose levels, supports weight reduction, and improves insulin sensitivity.
Administered as a subcutaneous injection once weekly in the abdomen, thigh, or upper arm. One prefilled pen provides four consecutive doses, covering one month of treatment. Dosage and duration should be determined by a healthcare professional.
Contraindications
Side effects
